We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · November 24, 2020

Prognostic Model for Survival of Post-Platinum Patients With Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors

The Journal of Urology

 

Additional Info

The Journal of Urology
Five-Factor Prognostic Model for Survival of Post-Platinum Patients With Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors
J Urol 2020 Dec 01;204(6)1173-1179, G Sonpavde, J Manitz, C Gao, D Tayama, C Kaiser, D Hennessy, D Makari, A Gupta, SE Abdullah, G Niegisch, JE Rosenberg, DF Bajorin, P Grivas, AB Apolo, R Dreicer, NM Hahn, MD Galsky, A Necchi, S Srinivas, T Powles, TK Choueiri, GR Pond

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading